Financial Performance: CRISPR Therapeutics AG reported a revenue increase to US$892,000 in Q2 2025 but faced a significant net loss of US$208.55 million, raising concerns about rising costs and the company's financial sustainability.
Investment Outlook: The widening losses and increased expenses may impact investor sentiment and expectations regarding future funding needs and profitability timelines, despite ongoing clinical trials and potential growth opportunities in gene-editing technology.
CRSP
$55.97+Infinity%1D
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 73.41 USD with a low forecast of 40.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 73.41 USD with a low forecast of 40.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 56.250
Low
40.00
Averages
73.41
High
105.00
Current: 56.250
Low
40.00
Averages
73.41
High
105.00
Chardan
Buy
downgrade
$82 -> $74
2025-11-26
Reason
Chardan
Price Target
$82 -> $74
2025-11-26
downgrade
Buy
Reason
Chardan lowered the firm's price target on Crispr Therapeutics to $74 from $82 and keeps a Buy rating on the shares. The firm updated the company's model post the Q3 report.
Citi
Yigal Nochomovitz
Buy
downgrade
$87 -> $77
2025-11-12
Reason
Citi
Yigal Nochomovitz
Price Target
$87 -> $77
2025-11-12
downgrade
Buy
Reason
Citi analyst Yigal Nochomovitz lowered the firm's price target on Crispr Therapeutics to $77 from $87 and keeps a Buy rating on the shares.
JPMorgan
Brian Cheng
Overweight
downgrade
$70 -> $69
2025-11-11
Reason
JPMorgan
Brian Cheng
Price Target
$70 -> $69
2025-11-11
downgrade
Overweight
Reason
JPMorgan analyst Brian Cheng lowered the firm's price target on Crispr Therapeutics to $69 from $70 and keeps an Overweight rating on the shares. The firm views the company's Q3 report as inline.
Baird
Neutral
downgrade
$52 -> $44
2025-11-11
Reason
Baird
Price Target
$52 -> $44
2025-11-11
downgrade
Neutral
Reason
Baird lowered the firm's price target on Crispr Therapeutics to $44 from $52 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results which met expectations but where Casgevy represents a potential headwind.
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
